Delivery Order SPE2DB24D3015-SPE2DB25FGBCN
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed price contract valued at $12,267.73. This non-set-aside competitive award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The ultimate completion date...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) at a ceiling value of $1,846.22. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Xifaxan 550 mg tablets in quantities of 60 units, with a contract ceiling value of $1,640.75. This firm fixed-price delivery order, which is not set-aside, is scheduled for ultimate completion on August 21, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Xifaxan 550 mg tablets (60-count packages) under a firm fixed-price contract with a ceiling value of $13,089.77 and an ultimate completion date of September 15, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global...
- The Defense Logistics Agency (DLA) awarded a $12,851.51 delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Xifaxan 550 mg tablets (60-count). This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The order is scheduled for completion by September 24, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Xifaxan 550 mg tablets (60-count) with a ceiling value of $3,532.41. This competitive award, utilizing firm fixed-price terms, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $28,942.08. This firm fixed-price delivery order, which is expected to be completed by August 25, 2025, was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company maintains operations as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count packages) under a firm fixed-price contract with a ceiling value of $27,314.07. This is a non-set-aside award issued as a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The order is scheduled for ultimate completion on September 9, 2025, with performance taking place at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Xifaxan 550 mg tablets in unit dose packaging (60 units) with a contract ceiling value of $8,588.18. This competitively awarded, firm fixed price delivery order is scheduled for completion by September 26, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $43,495.06 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Xifaxan 550 mg tablets (60-count units). The contract, which represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, carries an ultimate completion date of September 4, 2025, and involves no set-aside designation, indicating competitive award status. Performance will be executed at...
- SPE2DB24D3015Indefinite Delivery Contract
- SPE2DB24D3015-SPE2DB25FGBCNDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Xifaxan 550 mg tablets (60 count) with a ceiling value of $2,804.05. This firm fixed-price delivery order, which is expected to be completed by September 26, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was made competitively with no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company holds a substantial prime IDC valued at $999,999,999.00 with DLA Troop Support Medical through December 2026, which serves as a comprehensive global pharmaceutical support vehicle enabling the supply of diverse medications, vaccines, and medical supplies to support military healthcare programs worldwide. This delivery order for Xifaxan, an antibiotic medication, exemplifies the company's role in fulfilling federal medical supply requirements across multiple therapeutic domains for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 9/25/25 |